Table 1.
Demographics and baseline characteristics (full analysis set).
| ASP0113 (n = 246) | Placebo (n = 255) | Total (N = 501) | |
|---|---|---|---|
| Recipient characteristics | |||
| Male sex | 137 (55.7) | 153 (60.0) | 290 (57.9) |
| Median age (IQR), years | 54 (43–61) | 54 (44–62) | 54 (44–62) |
| Race | |||
| White | 174 (70.7) | 183 (71.8) | 357 (71.3) |
| Asian | 50 (20.3) | 45 (17.6) | 95 (19.0) |
| Black or African American | 7 (2.8) | 6 (2.4) | 13 (2.6) |
| Other | 15 (6.1) | 21 (8.2) | 36 (7.2) |
| Strata | |||
| Related seropositive donor | 72 (29.3) | 63 (24.7) | 135 (26.9) |
| Related seronegative donor | 26 (10.6) | 28 (11.0) | 54 (10.8) |
| Unrelated seropositive donor | 73 (29.7) | 93 (36.5) | 166 (33.1) |
| Unrelated seronegative donor | 75 (30.5) | 71 (27.8) | 146 (29.1) |
| Most frequent indications for transplant | |||
| Acute myelogenous leukaemia | 96 (39.0) | 123 (48.2) | 219 (43.7) |
| Myelodysplastic syndrome | 49 (19.9) | 45 (17.6) | 94 (18.8) |
| Acute lymphocytic leukaemia | 34 (13.8) | 31 (12.2) | 65 (13.0) |
| Lymphoma | 31 (12.6) | 32 (12.5) | 63 (12.6) |
| Conditioning regimen | |||
| Myeloablative | 120 (48.8) | 122 (47.8) | 242 (48.3) |
| Non-myeloablative | 124 (50.4) | 131 (51.4) | 255 (50.9) |
| Missing | 2 (0.8) | 2 (0.8) | 4 (0.8) |
| ATG | |||
| Yes | 43 (17.5) | 45 (17.6) | 88 (17.6) |
| No | 203 (82.5) | 210 (82.4) | 413 (82.4) |
| Donor characteristics | |||
| Male | 147 (59.8) | 161 (63.1) | 308 (61.5) |
| Median age (IQR), years | 39 (27–51) | 37 (27–50) | 38 (27–51) |
| Race | |||
| White | 103 (41.9) | 112 (43.9) | 215 (42.9) |
| Asian | 49 (19.9) | 41 (16.1) | 90 (18.0) |
| Black or African American | 5 (2.0) | 5 (2.0) | 10 (2.0) |
| American Indian or Alaska native | 1 (0.4) | 1 (0.4) | 2 (0.4) |
| Other | 71 (28.9) | 86 (33.7) | 157 (31.3) |
| Unknown | 17 (6.9) | 10 (3.9) | 27 (5.4) |
Data are n (%) unless otherwise specified. ATG=anti-thymocyte globulin; IQR, interquartile range.